Amplo Biotechnology
CA - San DiegoBiotechnology
Focus: Amplo Biotechnology is a newly founded biotech company focused on developing treatments for congenital myasthenic syndromes, a rare neuromuscular disorder space. The company went public in 2023 despite being early-stage, signaling significant investor confidence in its therapeutic area.
Profile data last refreshed 23h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Amplo Biotechnology
AI assessmentNot HiringNo open roles listed right now. Follow Amplo Biotechnology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Open Jobs (0)
No open positions listed yet.
Interview Prep Quick Facts
Founded: 2023
Private Funding (SEC Form D)
Oct 2021
Help build intelligence for Amplo Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.